Biopharma Networking Safety Side effects 
Clarivate
OCTOBER 19, 2023
Drug candidates have a high rate of failure, as only 10% of de-novo drugs put through clinical trials finally obtain market approval, with the highest rate of attrition occurring at phase I and II of clinical trials (assessing safety, tolerability, dosage, efficacy, and side effects).
pharmaphorum
SEPTEMBER 28, 2022
In recent years, the biopharma market has become progressively complex. Payers must take into consideration not only the clinical efficacy of a drug, but also its safety profile, side effects, and cost-effectiveness, among other factors. Click here to read the full article.
PM360
JULY 13, 2023
However, due to conjugation instability and unfavorable safety profiles of currently available ADCs, we can still do more to ensure ADCs are more broadly available and amenable options for the patients who need them. What Is Your Company Currently Working On?
Expert insights. Personalized for you.
59 
Let's personalize your content